Media headlines about Amarin (NASDAQ:AMRN) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amarin earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.4921060463639 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Amarin (AMRN) opened at $3.63 on Thursday. The company has a debt-to-equity ratio of -1.48, a current ratio of 1.63 and a quick ratio of 1.32. Amarin has a 52-week low of $2.85 and a 52-week high of $4.60. The stock has a market capitalization of $1,023.89, a price-to-earnings ratio of -13.44 and a beta of 0.50.
Several equities analysts have issued reports on the company. ValuEngine upgraded Amarin from a “sell” rating to a “hold” rating in a research report on Saturday, November 4th. Zacks Investment Research downgraded Amarin from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th. BidaskClub upgraded Amarin from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Amarin in a research report on Thursday, November 2nd. Finally, Cantor Fitzgerald set a $10.00 price objective on Amarin and gave the company a “buy” rating in a research report on Thursday, January 4th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Amarin currently has a consensus rating of “Hold” and an average price target of $7.75.
Amarin Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.